不同剂量米非司酮治疗子宫肌瘤的临床效果比较

目的：探讨不同剂量米非司酮治疗子宫肌瘤的临床效果。方法选取2013年1月～2014年2月在本院就诊的子宫肌瘤患者85例，随机分为观察组42例和对照组43例。对照组给予米非司酮片12.5 mg，观察组给予米非司酮片25 mg，比较两组的临床疗效、子宫肌瘤体积、不良反应发生率及血清FSH、LH、E2、P水平。结果观察组的总有效率为95.24%，明显高于对照组的83.72%，两组比较差异有统计学意义（P〈0.05）。两组治疗后的子宫肌瘤体积明显小于治疗前，差异有统计学意义（P〈0.05）。两组治疗后的子宫肌瘤体积比较，差异无统计学意义（P〉0.05）。两组治疗前后的血清FSH、LH、E2、P水平比较，差异有统计学意义（P〈0.05）。观察组治疗后的血清FSH、LH、E2、P水平明显低于对照组（P〈0.05）。观察组的不良反应发生率为21.43%，明显高于对照组的9.30%，两组比较差异有统计学意义（P〈0.05）。结论25 mg/（次·d）的米非司酮是治疗子宫肌瘤的有效剂量，可以提高临床疗效，但不良反应发生率高于小剂量组。

Clinical effect comparison on different doses of mifepristone in the treat-ment of uterine fibroid

Objective To discuss clinical effect on different doses of mifepristone in the treatment of uterine fibroid. Methods 85 patients with uterine fibroid from January 2013 to February 2014 in our hospital were collected and ran-domly divided into observation group（42 cases）and control group（43 cases）.Mifepristone tablet 12.5 mg was used in con-trol group,mifepristone tablet 25 mg was used in observation group.The clinical effect,size of uterine fibroid,incidence rate of adverse reaction and serum FSH,LH,E2,P in two groups was compared respectively. Results The total effective rate of observation group was 95.24%,significantly higher than that of control group （83.72%）,with statistical difference （P〈0.05）.After treatment,size of uterine fibroid in two groups was obviously less than before treatment respectively,with statistical difference（P〈0.05）.After treatment,size of uterine fibroid in two groups was compared,with no statistical difference（P〉0.05）.The serum FSH,LH,E2,P level in two groups was compared respectively before and after treatment,with statistical difference （P〈0.05）.After treatment,the serum FSH,LH,E2,P level in observation group was obviously lower than that in control group respectively（P〈0.05）.Incidence rate of adverse reaction in observation group was 21.43%,obviously higher than that in control group （9.30%）,with statistical difference （P〈0.05）. Conclusion 25 mg/（tim·d） is the effective dose of mifepristone in the treatment of uterine fibroid,can improve the clinical efficacy,but the incidence rate of adverse reaction is higher than that low dose group.